Status:
COMPLETED
Predictive Immune Biomarkers for COVID-19 Pathogenesis
Lead Sponsor:
University Hospital, Toulouse
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viral pneumopathy that can progress to acute respiratory distress syndrome (ARDS). The host-pathogen relationships and the ph...
Detailed Description
The World Health Organization (WHO) has recently declared pandemic the coronavirus disease 2019 (COVID-19) due to the causative severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 (SARS-CoV-2...
Eligibility Criteria
Inclusion
- For COVID-19 hospitalized patients
- Polymerase chain reaction (PCR) proven SARS-CoV-2 infection
- Participation to Toulouse clinical cohort
- Having signed consent for inclusion in the Toulouse biobanks
- For COVID-19 healthcare workers attending dedicated clinics
- PCR proven SARS-CoV-2 infection
- Having signed consent for inclusion in the Toulouse biobanks
Exclusion
- Pregnancy or breastfeeding
- Participation in another interventional clinical study involving exploratory treatment or blood sampling.
Key Trial Info
Start Date :
March 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 24 2021
Estimated Enrollment :
565 Patients enrolled
Trial Details
Trial ID
NCT04385108
Start Date
March 4 2020
End Date
December 24 2021
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Purpan University Hospital
Toulouse, France, 31059